What Is Retatrutide? Mechanism, Trials & Current Research

Retatrutide (LY3437943) is an investigational synthetic peptide that activates three receptors: glucagon, GIP and GLP-1. Phase 3 results for TRIUMPH-1 (New England Journal of Medicine) and TRIUMPH-2 (The Lancet) were published in September 2026, [5][6] and further phase 3 trials are ongoing. It is not approved anywhere.

Retatrutide, development code LY3437943, is a synthetic peptide designed to activate three receptors at once: the glucagon receptor, the GIP receptor and the GLP-1 receptor. Because it acts on three separate targets, it is described as a triple agonist, meaning a molecule that switches on three receptors rather than one. It is investigational, which means no regulator has approved it for any use anywhere, and the evidence for it so far comes only from controlled trials.

To understand why that combination matters, it helps to know what each receptor normally does in the body. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones, meaning they are released from the gut after eating and tell the pancreas to release insulin, but only when blood sugar is already elevated. They also slow the rate at which the stomach empties and act on appetite centres in the brain, which is why drugs that mimic them are associated with eating less and feeling fuller for longer. Glucagon is a different kind of hormone: it is normally released between meals to raise blood sugar by prompting the liver to release stored glucose, and it is also involved in how much energy the body burns. Retatrutide is built to engage all three signalling pathways with a single molecule, rather than the one or two that earlier drugs in this class targeted.

The receptor work behind it found that retatrutide has balanced strength at the glucagon and GLP-1 receptors, with relatively stronger activity at the GIP receptor when tested in isolated cells (an in vitro study, meaning outside a living organism). In obese mice, the weight effect was attributed to two combined mechanisms: glucagon receptor activity raising energy expenditure, and GIP and GLP-1 receptor activity lowering calorie intake. A phase 1 study, the first small human trial of a drug that checks dosing and safety, gave single rising doses and found pharmacokinetics, meaning how a drug moves through and is cleared from the body, that supported once-weekly dosing. Weight reduction was still measurable 43 days after a single dose. [1]

It is worth pausing on what a phase 1 study can and cannot tell us. Its job is narrow: confirm that a compound is cleared from the body at a rate that fits a practical dosing schedule, and check for obvious safety problems in a small number of people. It is not designed to show whether a drug works for its intended purpose in a larger population, which is what phase 2 and phase 3 trials exist to test. Each phase answers a different question, and skipping ahead to weight-loss percentages from a phase 1 study would be reading more into it than the design allows.

Retatrutide is an investigational compound. Every outcome figure on this page comes from a clinical trial conducted under supervision, and none of it describes a use, a quantity, or a result for a research material.

In short: higher doses produced larger average weight loss, up to roughly a quarter of starting body weight at the highest dose over 48 weeks, but also came with more side effects and higher dropout. The trial randomised 338 adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, across a placebo arm and six retatrutide arms covering 1, 4, 8 and 12 mg weekly with different starting doses. The primary endpoint, the main outcome a trial is designed to measure, was percent weight change at 24 weeks, with treatment continuing to 48 weeks. [2]

A few design features are worth unpacking because they explain why the trial is treated as strong evidence. It was randomised, meaning participants were assigned to placebo or a dose group by chance rather than choice, which prevents healthier or more motivated people from clustering into the drug arms. It was also placebo-controlled and double-blind, meaning neither participants nor the researchers assessing them knew who was receiving the active drug, which reduces the chance that expectation alone shapes the reported results. Several retatrutide arms used dose-escalation, meaning participants started on a lower amount and increased gradually toward the target dose, a common strategy for reducing early side effects rather than starting everyone at the full amount immediately.

HUMAN CLINICAL TRIAL

These are averages, and averages hide how much people vary. Threshold data at 48 weeks show the spread: at least 5, 10 and 15% weight reduction was reached by 92, 75 and 60% of the 4 mg group; 100, 91 and 75% of the 8 mg group; and 100, 93 and 83% of the 12 mg group, against 27, 9 and 2% on placebo. In the 12 mg group, 26% reached at least 30% reduction. [2] In plain terms, most people on the higher doses lost a clinically meaningful amount of weight, but a minority lost much more than the average and a minority lost much less, so the mean alone does not describe any one person's likely result.

What this data block shows: a randomised, placebo-controlled comparison across four doses, with both average results and the spread around them, over a defined 48-week period in a specific population. What it does not show: how the drug performs beyond 48 weeks, how it performs in populations excluded from the trial, or what happens to weight after treatment stops, since the trial was not designed to answer any of those questions.

338

participants

48 weeks

trial duration

−24.2%

mean weight change, 12 mg

−2.1%

placebo

The most common side effects were gastrointestinal: nausea, diarrhoea, vomiting and constipation. These occurred more often at higher doses and were mostly mild to moderate in severity, and starting on a lower dose before increasing it partly reduced them. Any adverse event during treatment occurred in 70 to 94% of retatrutide participants against 70% on placebo, and serious adverse events occurred in 3 to 6% across arms. One death was reported, in the 8 mg group that had started at a 2 mg dose. [2]

Adverse events are reported per arm, meaning as a percentage of the people assigned to each dose, rather than as a single overall figure, because that is the only way to see whether side effects track with dose. A single combined percentage across the whole trial would blur together a 1 mg group that tolerated the drug well with a 12 mg group that did not, hiding exactly the pattern the trial was designed to detect. Reading the arm-by-arm breakdown is what makes the dose-dependent rise in side effects visible in the first place.

Discontinuation because of adverse events, meaning participants who stopped the drug due to side effects, ranged from 0% in the 1 mg group to 16% in the 12 mg group, with an overall rate of 8% across the 337 retatrutide participants. Nausea-related discontinuation specifically was 1% overall. [2]

The 12 mg arm produced both the largest mean weight change and the highest discontinuation rate. Reporting one without the other would misrepresent the trial: the benefit and the tolerability cost rose together.

The headline finding is that retatrutide lowered HbA1c, a blood test that reflects average blood sugar over roughly three months, more than both placebo and an approved comparator drug, while also reducing body weight. HbA1c measures the fraction of red blood cells that have sugar molecules attached to them; because those cells persist for weeks, the test gives a rolling average rather than a single blood-sugar reading taken on one day, which is why trials use it as the standard marker of long-term glycaemic control.

A separate 36-week phase 2 trial randomised 281 adults with type 2 diabetes, HbA1c between 7.0 and 10.5%, and BMI 25 to 50, across placebo, dulaglutide 1.5 mg (an approved GLP-1 receptor agonist used as an active comparator), and retatrutide from 0.5 mg to 12 mg with different escalation schedules. The primary endpoint was HbA1c change at 24 weeks. [3]

HUMAN CLINICAL TRIAL

Of the 281 people randomised, 237 (84%) completed the study and 222 (79%) completed study treatment, meaning the numbers above reflect most but not all of the original group. Gastrointestinal adverse events occurred in 35% of retatrutide participants overall, ranging from 13% to 50% depending on arm, against 13% on placebo and 35% on dulaglutide. No severe hypoglycaemia (dangerously low blood sugar) and no deaths were reported. [3]

Dulaglutide is included in that table because it was a randomised arm within the same trial, so the comparison with it is a direct, head-to-head one, unlike comparisons drawn across separate studies with different populations and designs. A head-to-head comparison inside one trial controls for factors like which participants were enrolled, how outcomes were measured, and when they were measured, so differences between arms are more likely to reflect the drugs themselves rather than differences in how two separate studies were run.

What this data block shows: that adding glucagon receptor activity to the GIP and GLP-1 mechanisms did not come at the cost of blood-sugar control, and that the effect on HbA1c compared favourably with an approved drug tested in the same trial. What it does not show: long-term outcomes such as diabetes complications, cardiovascular events, or durability of glucose control beyond the 24 and 36-week windows measured here.

Every figure discussed above is a mean, meaning the arithmetic average of everyone in that dose group. A mean can be reached by everyone clustering close to it, or by a wide spread of very different individual results that happen to average out to the same number, and a single percentage cannot distinguish between those two very different situations.

The threshold data reported in the obesity trial is one way researchers address this: instead of only reporting that the 12 mg group averaged minus 24.2%, the trial also reports what fraction of that group reached at least 5%, 10%, 15% or 30% weight reduction. [2] That breakdown is what allows the statement that most people on higher doses had a clinically meaningful response, while also being honest that responses ranged from modest to very large within the same dose group. A mean by itself would not support either of those more specific statements.

A confidence interval, though not itemised figure by figure in the summaries above, is the standard statistical tool trials use to express how much a reported average might shift if the same trial were repeated with a different random sample of similar people; a narrower interval implies a more precise estimate. Readers encountering trial results elsewhere should expect to see this alongside a mean, and its absence in a claim is a reason to look for the underlying publication before treating a number as precise.

Two phase 3 trials have now been published in peer-reviewed journals: TRIUMPH-1, in adults with obesity without diabetes, in the New England Journal of Medicine on 29 September 2026, [5] and TRIUMPH-2, in adults with obesity and type 2 diabetes, in The Lancet (online 29 September 2026). [6] In TRIUMPH-1, 2,339 participants were randomised to retatrutide 4 mg, 9 mg or 12 mg or placebo for 80 weeks; using the primary treatment-regimen estimand, mean body-weight change was -17.6%, -23.7% and -25.0% versus -3.9% with placebo. [5] Figures quoted in news coverage and sponsor press releases can differ from the published ones because analysis methods differ, so compare like with like. Eli Lilly announced topline TRIUMPH-3 results in July 2026; we did not identify a peer-reviewed TRIUMPH-3 publication as of 14 October 2026. Lilly has stated it intends to submit retatrutide for regulatory review in the United States in the first quarter of 2027. Retatrutide remains an investigational compound.

Retatrutide's phase 3 programme, TRIUMPH, is broader than the two trials it is usually described by. At least 14 phase 3 trials are registered across obesity, type 2 diabetes, cardiovascular and kidney outcomes, an active-comparator study against tirzepatide, and weight maintenance. On 14 October 2026, 14 phase 3 studies of retatrutide were listed on ClinicalTrials.gov; five were marked completed and none had posted registry results. Because registry statuses change as studies progress, the trial-by-trial detail lives on one page rather than being repeated across the library. [4]

For each registered trial with its enrolment, status and publication state, see Retatrutide clinical trials.

Registered, completed, results posted and peer-reviewed published are four different things. A trial can be complete and still have published nothing. Topline figures that appear in news coverage before publication originate from company communications, not from a journal, and are not treated as evidence here.

Peer review is the process by which other scientists who were not involved in a study examine its methods and data before a journal publishes it, checking things like whether the statistics were appropriate and whether the conclusions match what the data actually show. It is not a guarantee that a study is correct, but its absence means a claim has not yet passed even that first layer of independent scrutiny, which is where parts of the TRIUMPH programme, such as TRIUMPH-3, known only from topline announcements, still sit.

Retatrutide is not approved in the United States, the European Union or elsewhere. Regulatory submission has been described as pending in industry coverage, which again is press reporting rather than a regulatory decision, and should be read with that distinction in mind.

For the receptor-level detail, continue to How does retatrutide work?.

For a side-by-side reading against the approved dual agonist, see tirzepatide and retatrutide compared.